The 2026-27 Union Budget announced major mission-mode investments in science, but experts highlight a persistent mismatch between headline allocations and the reality of core funding. While big-ticket programs like Biopharma SHAKTI get attention, basic research, state universities, and timely fund disbursement continue to face stagnation, raising questions about India's R&D ecosystem's long-term health.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Biopharma SHAKTI Outlay: ₹10,000 crore over five years
- ›Astronomy Facilities Upgrade: ₹3,500 crore
- ›Target this Data: Biopharma SHAKTI outlay is ₹10,000 crore over five years.
- ›Target this Nodal Body: Department of Biotechnology (DBT) and Department of Science & Technology (DST) are the key science funding departments.
- ›Target this Legal Point: The transition is from the Science and Engineering Research Board (SERB) to the Anusandhan National Research Foundation (ANRF).
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.